Go Back
This abstract was viewed 115 times

Review article

Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer

Daniel Corey OppenheimerEric P WeinbergGary M HollenbergSteven P Meyers
Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA
Date of Submission: 22-Mar-2016, Date of Acceptance: 14-Apr-2016, Date of Web Publication: 29-Apr-2016.
Corresponding Author:
Corresponding Author

Daniel Corey Oppenheimer, M.D.,

E-mail: Daniel_Oppenheimer@ URMC.Rochester.edu

Corresponding Author:
Corresponding Author

Daniel Corey Oppenheimer, M.D.,

E-mail: Daniel_Oppenheimer@ URMC.Rochester.edu

DOI: 10.4103/2156-7514.181494 Facebook Twitter Google Linkedin


Multiparametric magnetic resonance (MR) imaging of the prostate combines both morphological and functional MR techniques by utilizing small field of view T1-weighted, T2-weighted, diffusion-weighted imaging, dynamic contrast-enhanced imaging, and MR spectroscopy to accurately detect, localize, and stage primary and recurrent prostate cancer. Localizing the site of recurrence in patients with rising prostate-specific antigen following treatment affects decision making regarding treatment and can be accomplished with multiparametric prostate MR. Several different treatment options are available for prostate cancer including radical prostatectomy, external beam radiation therapy, brachytherapy, androgen deprivation therapy, or a number of focal therapy techniques. The findings of recurrent prostate cancer can be different depending on the treatment the patient has received, and the radiologist must be able to recognize the variety of imaging findings seen with this common disease. This review article will detail the findings of recurrent prostate cancer on multiparametric MR and describe common posttreatment changes which may create challenges to accurate interpretation.
Keywords: Biochemical recurrence, diffusion weighted imaging, dynamic contrast enhanced imaging, multiparametric prostate magnetic resonance

Cited in 11 Documents

  1. Deborah K. Hill, Andreas Heindl, Konstantinos Zormpas-Petridis, David J. Collins, Leslie R. Euceda, Daniel N. Rodrigues, Siver A. Moestue, Yann Jamin, Dow-Mu Koh, Yinyin Yuan, Tone F. Bathen, Martin O. Leach and Matthew D. Blackledge (2017) Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model. Front. Oncol. 7:. doi: 10.3389/fonc.2017.00290
  2. Helen Teixeira, Myungkuk Kang, Kathryn Lees, Sharon Beesley, Albert Edwards and Alastair Henderson (2019) Brachytherapy for the urologist: A multidisciplinary team update for 2019. Journal of Clinical Urology :205141581984170. doi: 10.1177/2051415819841703
  3. Giampiero Giovacchini, Elisabetta Giovannini, Rossella Leoncini, Mattia Riondato and Andrea Ciarmiello (2017) PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. Eur J Nucl Med Mol Imaging 44(10):1751. doi: 10.1007/s00259-017-3700-x
  4. Ryan L. Brunsing, Natalie M. Schenker-Ahmed, Nathan S. White, J. Kellogg Parsons, Christopher Kane, Joshua Kuperman, Hauke Bartsch, Andrew Karim Kader, Rebecca Rakow-Penner, Tyler M. Seibert, Daniel Margolis, Steven S. Raman, Carrie R. McDonald, Nikdokht Farid, Santosh Kesari, Donna Hansel, Ahmed Shabaik, Anders M. Dale and David S. Karow (2017) Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. J. Magn. Reson. Imaging 45(2):323. doi: 10.1002/jmri.25419
  5. D. Portalez and G. Ploussard (2019) Resonancia magnética funcional de la próstata. EMC - Urología 51(1):1. doi: 10.1016/S1761-3310(19)41720-9
  6. Marieke van Son, Max Peters, Marinus Moerland, Linda Kerkmeijer, Jan Lagendijk and Jochem van der Voort van Zyp (2018) Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. Cancers 10(12):480. doi: 10.3390/cancers10120480
  7. Catarina Dinis Fernandes, Petra J. van Houdt, Stijn W.T.P.J. Heijmink, Iris Walraven, Rick Keesman, Milena Smolic, Ghazaleh Ghobadi, Henk G. van der Poel, Ivo G. Schoots, Floris J. Pos and Uulke A. van der Heide (2018) Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external-beam radiation therapy. J. Magn. Reson. Imaging :. doi: 10.1002/jmri.26581
  8. Spencer T. Lake, Kirsten L. Greene, Antonio C. Westphalen, Spencer C. Behr, Ronald Zagoria, Eric J. Small, Peter R. Carroll and Thomas A. Hope (2017) Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res 7(1):. doi: 10.1186/s13550-017-0327-7
  9. Oladunni Akin-Akintayo, Funmilayo Tade, Pardeep Mittal, Courtney Moreno, Peter T. Nieh, Peter Rossi, Dattatraya Patil, Raghuveer Halkar, Baowei Fei, Viraj Master, Ashesh B. Jani, Hiroumi Kitajima, Adeboye O. Osunkoya, Claudia Ormenisan-Gherasim, Mark M. Goodman and David M. Schuster (2018) Prospective evaluation of fluciclovine ( 18 F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. European Journal of Radiology 102:1. doi: 10.1016/j.ejrad.2018.02.006
  10. Joan C. Vilanova, Violeta Catalá, Sandra Baleato and Joaquim Barceló (2018) Atlas of Multiparametric Prostate MRI. (Chapter 7):143. doi: 10.1007/978-3-319-61786-2_7
  11. Andreas M. Hötker, Andreas Meier, Yousef Mazaheri, Junting Zheng, Marinela Capanu, Joshua Chaim, Ramon Sosa, Jonathan Coleman, Hedvig Hricak and Oguz Akin (2019) Temporal changes in MRI appearance of the prostate after focal ablation. Abdom Radiol 44(1):272. doi: 10.1007/s00261-018-1715-9

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.